# Filing Detail

Form 424B5 - Prospectus [Rule 424(b)(5)]:
SEC Accession No. 0001193125-25-168035
Filing Date
2025-07-29
Accepted
2025-07-29 16:34:12
Documents
4

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 424B5 | d12792d424b5.htm | 424B5 | 489532
2 | GRAPHIC | g12792g00a01.jpg | GRAPHIC | 601923
3 | GRAPHIC | g12792g00a04.jpg | GRAPHIC | 605282
4 | GRAPHIC | g12792g00a38.jpg | GRAPHIC | 611181
| Complete submission text file | 0001193125-25-168035.txt |  | 2960009

Mailing Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004
Business Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004 844-511-9056
Larimar Therapeutics, Inc. (Filer) CIK: 0001374690 (see all company filings)

EIN.: 203857670 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 424B5 | Act: 33 | File No.: 333-279275 | Film No.: 251162301
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)